BioNTech SE (22UA) - Total Assets
Based on the latest financial reports, BioNTech SE (22UA) holds total assets worth €21.07 Billion EUR (≈ $24.64 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check BioNTech SE total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
BioNTech SE - Total Assets Trend (2016–2025)
This chart illustrates how BioNTech SE's total assets have evolved over time, based on quarterly financial data. Explore BioNTech SE strategic investment ratio to see how much of total assets are deployed in long-term investments.
BioNTech SE - Asset Composition Analysis
Current Asset Composition (December 2025)
BioNTech SE's total assets of €21.07 Billion consist of 73.4% current assets and 26.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 34.9% |
| Accounts Receivable | €924.20 Million | 4.2% |
| Inventory | €110.70 Million | 0.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.61 Billion | 7.3% |
| Goodwill | €367.90 Million | 1.7% |
Asset Composition Trend (2016–2025)
This chart illustrates how BioNTech SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 22UA company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioNTech SE's current assets represent 73.4% of total assets in 2025, a decrease from 81.6% in 2016.
- Cash Position: Cash and equivalents constituted 34.9% of total assets in 2025, down from 77.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 2.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 7.3% of total assets.
BioNTech SE Competitors by Total Assets
Key competitors of BioNTech SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
BioNTech SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.80 | 10.18 | 2.67 |
| Quick Ratio | 8.74 | 10.02 | 2.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €13.77 Billion | €14.09 Billion | €5.28 Billion |
BioNTech SE - Advanced Valuation Insights
This section examines the relationship between BioNTech SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.07 |
| Latest Market Cap to Assets Ratio | 0.91 |
| Asset Growth Rate (YoY) | -2.4% |
| Total Assets | €21.99 Billion |
| Market Capitalization | $20.05 Billion USD |
Valuation Analysis
Near Book Valuation: The market values BioNTech SE's assets close to their book value (0.91x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: BioNTech SE's assets decreased by 2.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for BioNTech SE (2016–2025)
The table below shows the annual total assets of BioNTech SE from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €21.99 Billion ≈ $25.71 Billion |
-2.40% |
| 2024-12-31 | €22.53 Billion ≈ $26.34 Billion |
-2.07% |
| 2023-12-31 | €23.01 Billion ≈ $26.90 Billion |
-1.17% |
| 2022-12-31 | €23.28 Billion ≈ $27.22 Billion |
+47.05% |
| 2021-12-31 | €15.83 Billion ≈ $18.51 Billion |
+582.77% |
| 2020-12-31 | €2.32 Billion ≈ $2.71 Billion |
+190.68% |
| 2019-12-31 | €797.65 Million ≈ $932.53 Million |
+22.15% |
| 2018-12-31 | €652.99 Million ≈ $763.41 Million |
+74.26% |
| 2017-12-31 | €374.71 Million ≈ $438.08 Million |
-3.91% |
| 2016-12-31 | €389.96 Million ≈ $455.90 Million |
-- |
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic tr… Read more